Cancer drug niraparib tested before prostate surgery – early trial stopped

NCT ID NCT04030559

Terminated Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested the drug niraparib (Zejula) in 11 men with high-risk prostate cancer that had not spread. All men had specific DNA repair gene mutations. They took niraparib before having their prostate removed surgically. The goal was to see if the drug could eliminate or shrink the tumor before surgery. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Niraparib (a PARP inhibitor drug, brand name Zejula)
What this could lead to: If it works, this could point toward a treatment that shrinks prostate tumors before surgery, potentially improving outcomes for men with certain genetic mutations.
What could go wrong: This trial was terminated early with only 11 participants, so results are very limited. It is unclear if niraparib is effective or safe in this setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATM GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATM GENE MUTATION BRCA1 GENE MUTATION BRCA2 GENE MUTATION BRIP1 GENE MUTATION CDK12 GENE MUTATION CHEK1 GENE MUTATION CHEK2 GENE MUTATION DNA DAMAGE RESPONSE GENE MUTATION DNA REPAIR GENE MUTATION FANCA GENE MUTATION FANCD2 GENE MUTATION FANCL GENE MUTATION GEN1 GENE MUTATION NBN GENE MUTATION PROSTATE CARCINOMA RAD51 GENE MUTATION RAD51C GENE MUTATION

Contacts and locations

Locations

University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.